| Literature DB >> 11498827 |
Abstract
The amplification or overexpression of HER-2 is a recognized prognostic marker that is associated with poor survival for patients with node-positive breast cancer. Several studies have demonstrated that HER-2 may serve to direct the selection of optimal adjuvant chemotherapy. This article provides a critical review of the studies that offer evidence for the role of HER-2 as a predictor of response to chemotherapy.Entities:
Mesh：
Year: 2001 PMID： 11498827 DOI： 10.1016/s0093-7754(01)90127-7
Source DB: PubMed Journal: Semin Oncol ISSN： 0093-7754 Impact factor: 4.929